youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
Policy Impact Assessment: The VHA’s Post-2012 Opioid Pivot and the Systemic Erosion of Veteran Care
THE OPIOID NUISANCE LAWSUIT
The 2012 Strategic Inflection Point: From Pain Management to SSRI Substitution
The year 2012 serves as the definitive strategic inflection point for the Veterans Health Administration (VHA), marking the absolute peak of opioid prescribing and the commencement of an aggressive, top-down reversal in clinical philosophy. This was not a nuanced refinement of care but a radical pivot away from physical medicine toward a psychological pathologization of suffering.
By prioritizing administrative de-prescribing targets over individual clinical necessity, the VHA fundamentally altered the contract of care for those with complex chronic pain.
The scale of this shift is staggering: following 2012, the VHA enforced a 30% to 40% annual reduction in opioid prescriptions. To fill the pharmacological vacuum, the system transitioned more than 1 million veterans to Selective Serotonin Reuptake Inhibitors (SSRIs). This massive substitution occurred despite a lack of longitudinal tracking for patient outcomes, effectively treating a physical crisis with a mental health intervention.
The “So What?” of the Strategic Pivot:
- The Pathologization of Pain: By replacing pain management with SSRI regimens, the VHA strategically categorized physical injury as a “mental defect.” This allowed the system to abandon the complexities of physical medicine and multidisciplinary pain clinics in favor of lower-cost behavioral management.
- Systemic Silencing: The pivot effectively rendered a specific demographic of veterans—those who were medically stabilized on chronic opioid therapy—functionally voiceless. As physical medicine departments were hollowed out, these patients lost their clinical advocates.
- Abandonment of Outcomes: Success was redefined through the lens of pill counts rather than veteran wellness. By failing to track the outcomes of the one million veterans transitioned to SSRIs, the VHA prioritized “data-driven” de-prescribing over human survival.
This clinical abandonment was not a byproduct of evolving science; it was a policy outcome enforced through a sophisticated array of regulatory mechanisms.
Legal Nullification and the Suspension of Due Process
The VHA’s transition was shielded by the strategic application of federal legislation and internal directives, which were weaponized to insulate the department from patient grievances. The Comprehensive Addiction and Recovery Act (CARA) and the Support Act, when combined with VHA Directive 1112, provided the administrative tools necessary to overhaul care while suppressing dissent. These mechanisms allowed for the “at-risk” labeling of veterans, a designation that served as a convenient tool for state-led censorship.
By labeling patients as “at-risk,” the VHA utilized CARA’s authority to bypass standard complaint procedures and restrict veteran advocacy. This maneuver did more than just create a procedural hurdle; it effectively and illegally nullified long-standing veteran protections.
| Statutory Protections (38 CFR 17.33 (g)) | Regulatory Actions & Failures |
| Right to Due Process: Guarantees veterans specific protections, including the right to be heard regarding medical treatment decisions and to file formal grievances without fear of retaliation. | Censorship Authority: CARA and the Support Act were weaponized to label veterans as “at-risk,” allowing the VHA to bypass due process and suppress complaints regarding forced tapering. |
| Mandatory Transparency: Federal law requires open communication, including townhalls, to address systemic changes in care and policy impacts on the veteran population. | Decade of Failure: For nearly ten years, the VHA has failed to provide the mandated townhalls and due process required to legally utilize the censorship authority granted by CARA. |
The “so what” regarding the “thumb on the research scale” is clear: by law and directive, research within the VHA was restricted to only affirming de-prescribing outcomes.
This ensured that no internal data could emerge to challenge the systemic pivot, effectively legally mandating a bias in clinical research. This internal suspension of due process served as the blueprint for the economic pressures exerted on the broader medical landscape through the “reimbursement cudgel.”
The Reimbursement Cudgel and the Collapse of Independent Pain Services
The federal government utilized its control over funding as a strategic tool to enforce the opioid pivot across the private sector. By leveraging Department of Justice (DOJ) actions and the threat of withdrawal of Medicare/Medicaid reimbursement—the “reimbursement cudgel”—the state forced independent providers to mirror the VHA’s de-prescribing mandates or face systemic elimination.
Independent, physician-owned pain management services were specifically targeted for closure and legal investigation, while internal VA and Medicare systems remained protected from similar scrutiny. The strategic rationale for this disparity is rooted in the control of information.
Strategic Insight: The Data Manipulation Gap. Independent clinics were viewed as a threat because their patient outcome data—often documenting the clinical necessity of chronic opioid therapy and high patient satisfaction—could not be manipulated “at the source” like data within the centralized VA and Medicare systems. To maintain the government’s narrative that “de-prescribing equals success,” providers who maintained independent data proving the contrary had to be removed from the market.
This cudgel ensured that clinical necessity was superseded by regulatory survival, clearing the path for a market narrative that justified the redistribution of industry profits.
THE SUPREME COURT OF MARYLAND overturnS Baltimore City Court’s $266 million judgment against pharmaceutical companies over the alleged effects of opioid distribution.
This legal opinion from the Supreme Court of Maryland addresses a certified question regarding whether the licensed distribution of opioids and the management of pharmacy benefit plans can be classified as a public nuisance under state common law.
The Court fundamentally rejects this expansion, holding that the public nuisance doctrine is a narrow historical concept intended to address interferences with common public rights, such as the obstruction of highways or waterways.
Because the pharmaceutical industry is already governed by an extensive federal and state regulatory framework, the Court emphasizes the importance of judicial restraint, concluding that complex societal issues like the opioid crisis are matters for the legislative branch rather than the courts.
Deconstructing the “Industry Profit” Narrative: Purdue vs. Generic Saturation
The government’s “bad faith” arguments regarding the opioid crisis focused almost exclusively on Purdue Pharma and the Sackler family to provide a civil and criminal justification for refilling state coffers. However, the market share data exposes a profound tension between this narrative and reality.
- The Pill Count Reality: While the public focus remains on Purdue, the company’s actual share of the opioid market by pill count was approximately 4.6% between 2006 and 2012.
- The Generic Flood: During that same window, generic manufacturers—specifically Actavis and Mallinckrodt—flooded the market with the vast majority of the 75 billion opioid pills distributed nationwide. Actavis alone saw oxycodone sales jump from 559 million to 1.1 billion pills by 2012.
- Potency Adjustment (MME) as a Target Tool: To justify focusing on the high-profile branded drug, regulators utilized “Morphine Milligram Equivalents” (MME). This allowed the government to inflate Purdue’s “impact” to 31.2% in states like Rhode Island, maintaining a legal bullseye on the Sacklers while ignoring the billions of generic pills fueling the crisis.
The “So What?” of the Narrative Shift: The focus on Purdue served as a strategic distraction from systemic regulatory failures. It allowed the FDA to sidestep accountability for its own “lax oversight,” “cozy ties with industry,” and the approval of drugs based on single, limited trials. By making the Sacklers the symbolic villains, the government successfully secured bankruptcy settlements ranging from $6 to $7.4 billion, refilling its own coffers while ignoring the role of the generic manufacturers and the FDA’s own failure to report suspicious orders.
Ethical Implications: Judging by Probability vs. Clinical Necessity
The systemic shift within the VHA represents a departure from the “moral bedrock” of Western jurisprudence, which evaluates individuals based on their “ability to have done otherwise.” This framework requires an assessment of context, necessity, and clinical justification. In its place, the VHA has substituted a model of judging patients based on AI-driven “probability scores” and risk-adjustment analytics.
When a veteran is reduced to a data point on a probability scale, the clinical necessity of their care is sacrificed for administrative efficiency. This trade-off has profound ethical consequences.
Moral Bedrock Issues in Data-Driven Care:
- The Erasure of Necessity: Probability scores treat all opioid use as a statistical risk to be mitigated, regardless of the patient’s actual physical condition or clinical requirement for relief.
- Institutional Bias: Data analytics are regulatorily “weighted” to favor pre-determined policy outcomes, such as de-prescribing, rather than discovering objective clinical truths about veteran health.
- Redistribution as Objective: The ultimate priority of these systemic shifts has been the redistribution of industry profits into state and federal coffers, rather than the restoration of the veterans who were harmed by the policy shift itself.
Bottom Line Up Front (BLUF): The evidence demonstrates that patients—specifically veterans—have become the primary casualties in a state-led effort to punish industry and redistribute profits.
In a bad-faith effort to secure massive settlements and maintain the “reimbursement cudgel,” the VHA and the federal government have prioritized data manipulation and “at-risk” censorship over the clinical necessity of those they are sworn to care for.
One million veterans remain silent, untracked, and effectively abandoned by a system that traded their well-being for a refined government balance sheet.
“Kangaroo TribunalS”
Congressional oversight is not just a suggestion; it is the only thing standing between a healthcare provider and a “Kangaroo Tribunal” that treats educated professionals as “low-hanging fruit” for the prison-industrial complex. We must demand a return to an Article III standard, where justice is administered “without respect to persons.”
Dr. Rifia…. “struggle reveal that these agencies’ intrusions and overreaches are built on half-truths that support their foundation of Judicial Architectural Deception to imprison more medical providers with the utmost efficiency.”
🔓 🔓 🔓
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
OUR TREE OF KNOWLEDGE SHALL NEVER BE SUPPRESSED
FOR NOW, YOU ARE WITHIN
THE NORMS
REFERENCE:
THE WRONG COURTHOUSE!!!
NO INVESTIGATION RICHARD JAMES ALBERT
THE HOLY TRINITY
B. The Pharmacological Trinity-1 While opioids target G-protein-coupled receptors to block pain signals, benzodiazepines enhance GABAergic inhibition to provide necessary sedation and muscle relaxation. This synergistic approach allows for lower medication doses, which effectively reduces adverse side effects while extending the duration of relief. Beyond clinical mechanics, the text uses a theological metaphor of the Holy Trinity to illustrate how these distinct agents work in dynamic communion to heal the patient. Ultimately, the goal of this integrated therapy is to restore the individual’s quality of life, enabling them to return to employment, mobility, and social connection.
